Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1573691 | 0.91 | FDPS (0.36) | FDPS | |
| SCHEMBL5444402 | 0.91 | FDPS (0.36) | FDPS | |
| SCHEMBL14686406 | 0.84 | FDPS (0.32) | FDPS | |
| SCHEMBL25410807 | 0.80 | — | — | |
| SCHEMBL4316538 | 0.78 | — | — | |
| SCHEMBL527878 | 0.73 | — | — | |
| SCHEMBL15345896 | 0.73 | HDAC1 (0.36) | FDPS | |
| SCHEMBL11237996 | 0.72 | — | — | |
| SCHEMBL18537812 | 0.72 | MEN1 (0.33) | — | |
| Water SCHEMBL29635525 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11850294-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2023-12-26 | — | — | US | claimed |
| US-20220079849-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | FIDELITY DIRECT LENDING LLC, AS ADMINISTRATIVE AGENT | 2022-03-17 | — | — | US | claimed |
| US-11185480-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2021-11-30 | — | — | US | claimed |
| US-10688026-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2020-06-23 | — | — | US | claimed |
| US-20200016051-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | FIDELITY DIRECT LENDING LLC, AS ADMINISTRATIVE AGENT | 2020-01-16 | — | — | US | claimed |
| US-20190099335-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | PREMIER DENTAL PRODUCTS COMPANY | 2019-04-04 | — | — | US | claimed |
| US-20180200164-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | FIDELITY DIRECT LENDING LLC, AS ADMINISTRATIVE AGENT | 2018-07-19 | — | — | US | claimed |
| US-9814688-B2 | Antimicrobial compositions and methods for their use | DERMCARE-VET PTY LTD (AU) | 2017-11-14 | — | — | US | claimed |
| US-20170165208-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR USE | DERMCARE-VET PTY LTD (AU) | 2017-06-15 | — | — | US | claimed |
| US-9555015-B2 | Antimicrobial compositions and methods for their use | DERMCARE-VET PTY LTD (AU) | 2017-01-31 | — | — | US | claimed |
| EP-1755576-B1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR USE | DERMCARE VET PTY LTD (AU) | 2011-07-13 | — | — | EP | claimed |
| EP-1755576-A4 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR USE | DERMCARE VET PTY LTD (AU) | 2009-07-08 | — | — | EP | claimed |
| US-20070282008-A1 | Antimicrobial Compositions and Methods for Their Use | DEMCARE-VET PTY LTD (AU) | 2007-12-06 | — | — | US | claimed |
| EP-1755576-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR USE | DERMCARE-VET PTY LTD (AU) | 2007-02-28 | — | — | EP | claimed |
| WO-2005097094-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR USE | DERMCARE-VET PTY LTD (AU) | 2005-10-20 | — | — | WO | claimed |
| US-11850294-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2023-12-26 | — | — | US | disclosed |
| EP-2895323-B1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | PREMIER DENTAL PRODUCTS CO (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20130011453-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | PREMIER DENTAL PRODUCTS COMPANY (US) | 2013-01-10 | — | — | US | disclosed |
| EP-1755576-B1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR USE | DERMCARE VET PTY LTD (AU) | 2011-07-13 | — | — | EP | disclosed |
| US-20070282008-A1 | Antimicrobial Compositions and Methods for Their Use | DEMCARE-VET PTY LTD (AU) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688026-B2 | Buffered microencapsulated compositions and methods | LIPA, CHMP4B, APOB | FDPS 3224/4885OPRD1 4536/4885 |
| US-11185480-B2 | Buffered microencapsulated compositions and methods | CHMP4B, LIPA, APOB | FDPS 3233/4885OPRD1 4321/4885 |
| US-11850294-B2 | Buffered microencapsulated compositions and methods | CHMP4B, LIPA, APOB | FDPS 3233/4885OPRD1 4321/4885 |
| US-20170165208-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR USE | CUTA, PUF60, UNG | FDPS 4336/4885OPRD1 4427/4885 |
| US-20220079849-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | CHMP4B, LIPA, APOB | FDPS 3233/4885OPRD1 4321/4885 |
| US-20130011453-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | LIPA, CHMP4B, APOB | FDPS 3192/4885OPRD1 4481/4885 |
| US-20180200164-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | LIPA, CHMP4B, APOB | FDPS 3224/4885OPRD1 4536/4885 |
| US-20070282008-A1 | Antimicrobial Compositions and Methods for Their Use | CUTA, PUF60, UNG | FDPS 4336/4885OPRD1 4427/4885 |
| US-20200016051-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | CHMP4B, LIPA, APOB | FDPS 3233/4885OPRD1 4321/4885 |
| US-20190099335-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | LIPA, CHMP4B, APOB | FDPS 3210/4885OPRD1 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.